Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study

@article{Mross2004PharmacokineticsOL,
  title={Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study},
  author={K. Mross and B. Niemann and U. Massing and J. Drevs and C. Unger and R. Bhamra and C. Swenson},
  journal={Cancer Chemotherapy and Pharmacology},
  year={2004},
  volume={54},
  pages={514-524}
}
PurposeLiposomal encapsulation of doxorubicin is designed to increase safety and tolerability by decreasing cardiac and gastrointestinal toxicity through decreased exposure of these tissues to doxorubicin, while effectively delivering drug to the tumor. [...] Key MethodExperimental designPatients received a single intravenous infusion of Myocet 75 mg/m2. Plasma samples were analyzed for concentration of liposome-encapsulated doxorubicin, total doxorubicin, and doxorubicinol.Expand

Paper Mentions

Interventional Clinical Trial
Multicenter randomised phase II study of neoadjuvant therapy in HER2 positive early breast cancer. Primary aim is to evaluate the cardiac toxicity of the combined treatment… Expand
ConditionsBreast Cancer
InterventionDrug
Phase I study of non-pegylated liposomal doxorubicin in children with recurrent/refractory high-grade glioma
A phase IB dose-finding trial of liposomal doxorubicin in combination with capecitabine in patients with pretreated metastatic breast cancer
Liposomal Doxorubicin
Liposomal Doxorubicin in Breast Cancer
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 30 REFERENCES
Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.
  • G. Batist, G. Ramakrishnan, +10 authors L. Lee
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2001
Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer
Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin.
Doxorubicin and doxorubicinol: intra-and inter-individual variations of pharmacokinetic parameters
Epirubicin and doxorubicin comparative metabolism and pharmacokinetics
Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans.
...
1
2
3
...